Cytokinetics to Participate in June Investor Conferences
Cytokinetics, a specialty cardiovascular biopharmaceutical company, announced its management team's participation in major June investor conferences including Jefferies and Goldman Sachs. The company highlighted progress in its drug pipeline, notably the approved MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy, and upcoming present…